C12N 2750/14021
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2750/14021 (Viruses as such) appears on 10 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 17
- Assignees
- 8
- Inventors
- 47
- Latest grant
- 17 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 3 |
| 2015 | 1 | 4 |
| 2016 | 1 | 3 |
| 2017 | 3 | 0 |
| 2018 | 1 | 0 |
| 2019 | 2 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 2 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Murine parvovirus and uses thereof17 May 2022US 11,332,720 B2Centenary Institute of Cancer Medicine and Cell Biology
- Adeno-associated virus virions with variant capsid1 Feb 2022US 11,236,402 B2The Regents of the University of California
- Adeno-associated virus virions with variant capsid and methods of use thereof26 Feb 2019US 10,214,785 B2The Regents of the University of California
- Adeno-associated virus virions with variant capsid and methods of use thereof12 Feb 2019US 10,202,657 B2The Regents of the University of California
- Adeno-associated virus virions with variant capsid and methods of use thereof2 Jan 2018US 9,856,539 B2The Regents of the University of California
- Quantitative particle content assessment using hydrated state imaging and image analysis23 Jul 2026US 2026/0212690 A1Intelligent Virus Imaging Inc.
- Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity21 Aug 2025US 2025/0262296 A1
- Bidirectional dual promoter expression vectors and uses thereof23 Nov 2023US 2023/0374546 A1Homology Medicines, Inc.
- Treatment of cancer harboring mutations in the tp53 gene and/or post-translational modifications in the p53 protein with parvoviruses14 Sep 2023US 2023/0285481 A1
- Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof4 Aug 2022US 2022/0243291 A1The Regents of the University of California
Most cited
By later US patents
- Adeno-associated virus virions with variant capsid and methods of use thereof68US 9,458,517 B2The Regents of the University of California · 2016
- Adeno-associated virus virions with variant capsid and methods of use thereof65US 9,587,282 B2The Regents of the University of California · 2017
- Adeno-associated virus virions with variant capsid and methods of use thereof60US 9,193,956 B2The Regents of the University of California · 2015
- Adeno-associated virus virions with variant capsid and methods of use thereof25US 10,202,657 B2The Regents of the University of California · 2019
- Adeno-associated virus virions with variant capsid and methods of use thereof24US 9,856,539 B2The Regents of the University of California · 2018